viewTiziana Life Sciences PLC

Tiziana Life Sciences fleshes out demerger plans as it looks to unlock value from StemPrintER business

The newly-independent business will be called Accustem Science

Tiziana Life Sciences PLC -

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) expects its demerged StemPrintER business will be floated on the London Stock Exchange’s standard list late in the fourth quarter, followed potentially by a dual Nasdaq quote next year.

The new, independent diagnostics business will be known as Accustem Sciences, and the spin-off will allow Tiziana to focus on its clinical portfolio.

Tiziana is using dividend in specie to affect the split. This where a dividend is paid not in cash, but in assets of the company.

In the case of Tiziana, Accustem will receive the breast cancer diagnostic StemPrintER and the SPARE genomics-based personalised medicine business plus cash reserves of around £1mln. Accustem will then allot shares on a one-for-one basis to Tiziana investors.

Warrant-holders will be granted equivalent instruments in the demerged company, investors were told.

“Demerging the genomic risk assessment assay StemPrintER for breast cancer can enable the separate therapeutic and genomics entities to seek the most suitable independent funding or partnerships to move forwards and highlight the value of each segment as a ‘pure-play’,” Proactive analyst Emma Ulker said in a recent note on the company.

She pointed out that StemPrintER was shown in a retrospective study to be superior to the standard assay acquired by Exact Sciences as part of a US$2.8bn takeover deal.

For the demerger timetable click here 

Quick facts: Tiziana Life Sciences PLC

Price: 139 GBX

Market: AIM
Market Cap: £265.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...


Tiziana Life Sciences: Delivery method & data 'looks promising' ahead of...

Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially...

4 hours, 39 minutes ago

2 min read